Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

3.47
-0.1500-4.14%
Volume:367.44K
Turnover:1.26M
Market Cap:108.58M
PE:-0.84
High:3.58
Open:3.58
Low:3.35
Close:3.62
52wk High:49.25
52wk Low:3.35
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.91
T/O Rate:2.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.50
PE(LYR):-1.22

Loading ...

Halozyme Therapeutics Adds James Daly to Board

TIPRANKS
·
Oct 01

Analyst Reiterates Buy on Quince Therapeutics, Maintaining Unchanged $98 Price Target Amid Advancing Pulmonary Pipeline

TIPRANKS
·
Oct 01

Whitehawk Therapeutics initiated with a Buy at Stifel

TIPRANKS
·
Oct 01

Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer

GlobeNewswire
·
Oct 01

Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk

GlobeNewswire
·
Oct 01

Sarepta Therapeutics is Maintained at Neutral by JP Morgan

Dow Jones
·
Oct 01

EPIRUS Therapeutics: Buy Rating Reiterated on EP-104GI’s Emerging Clinical Profile and Upcoming Phase 2b Catalyst; $16 Price Target Unchanged

TIPRANKS
·
Oct 01

Keros Therapeutics Advances DMD Trial for KER-065, Keeping Rare Disease Upside in Play

TIPRANKS
·
Oct 01

Damora Therapeutics Advances CALR-Targeted Antibody Into Early Clinical Testing

TIPRANKS
·
Oct 01

CytoMed Therapeutics Posts Narrower Interim Loss in June 2026 SEC Filing

TIPRANKS
·
Sep 30

Indaptus Therapeutics Extends Timeline for Private Placement Financing

TIPRANKS
·
Sep 30

Silexion Therapeutics Begins Global SIL204 Pancreatic Cancer Trial

TIPRANKS
·
Sep 30

Cutia Therapeutics to Launch Up to 30 Million Yuan Share Buyback

MT Newswires Live
·
Sep 30

Cutia Therapeutics Unveils Targeted Share Buyback to Signal Confidence

TIPRANKS
·
Sep 30

Thalia Therapeutics Accelerates RNA Strategy With Sanmirna Deal and Clinical-Stage Pipeline

TIPRANKS
·
Sep 30

Shield Therapeutics updates total voting rights and share capital

TIPRANKS
·
Sep 30

AstraZeneca Secures $2 Billion Summit Therapeutics Oncology Partnership, Bolstering GI Cancer Pipeline and Supporting Buy Rating on AZN

TIPRANKS
·
Sep 30

Chordia Therapeutics Secures AMED Grant to Accelerate Global Development of Rogocekib

TIPRANKS
·
Sep 30

Prescient Therapeutics Issues New Class of Long-Dated Unquoted Options

TIPRANKS
·
Sep 30

Prescient Therapeutics Seeks ASX Quotation for 73.8 Million New Shares

TIPRANKS
·
Sep 30